Navigation Links
Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes.
Date:9/21/2012

SAN DIEGO, Sept. 21, 2012 /PRNewswire/ -- Medical Marijuana Inc. (OTC: MJNA), a leading hemp industry innovator, is pleased to report on a September 18 San Francisco Chronicle Article, "Pot compound seen as tool against cancer."

The article states that scientists at California Pacific Medical Center who have been researching marijuana's compounds for the 20 years have found that Cannabidiol, or CBD, has the ability to "turn off" the DNA that causes "breast and other types of cancers" to metastasize. CBD is the second-most abundant cannabinoid within marijuana, but does not cause the psychotropic high of THC.

As stated in the article: "We started by researching breast cancer," said scientist Pierre Desprez. "But now we've found that Cannabidiol works with many kinds of aggressive cancers--brain, prostate--any kind in which these high levels of ID-1 are present."

Desprez said he is hopeful clinical trials will begin immediately. He currently has grant funding through the National Institutes of Health, Susan G. Komen for the Cure, the U.S. Department of Defense and the California Breast Cancer Research Program.

As previously announced in the MJNA press release dated September 5, MJNA portfolio company, Red Dice Holdings, recently launched its Hemp-based high concentrate CBD health and wellness products, Dixie X, for over-the-counter sales. These Cannabidiol products represent the highest strength of CBD products on the market today, and this same concentrate will soon be used to launch the CanChew Biotechnologies line of CBD-enriched chewing gum.
'/>"/>

SOURCE Medical Marijuana Inc.
Copyright©2012 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Sabiya Donates Odor-Fighting Athletic Apparel to the Corps of Exploration Aboard E/V Nautilus
2. Bed Bugs Bite on Businesses, Green Bean Buddy Advises Owners to Fight Back With a Non-Toxic Bed Bug Bully Product
3. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
4. MU researchers identify key plant immune response in fight against bacteria
5. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
6. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
7. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
8. Life Sciences Venture Capital Funding Shrinks for Fourth Straight Quarter According to the MoneyTree Report
9. Van Andel Institute Research Symposium Showcases Latest Developments In Parkinsons Research
10. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
11. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Smarter Security, Inc., provider of ... announced that Genzyme, a Sanofi company and leading biotech ... CL for a multi-use facility in the United States. ... Genzyme buildings, this latest order underscores the satisfaction and ... detection device improving doorway access control. , ...
(Date:5/21/2013)... FL (PRWEB) May 21, 2013 Many ... breakouts as contributor to acne. Recently physicians from ... of mental stress on the skin, and suggested using ... help reduce the chemicals produced from stress that cause ... from the negative feelings acne brings about, stress causes ...
(Date:5/21/2013)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... diseases, announced today that Jeffrey Riley , ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. Mr. Riley is scheduled to present at 10:00 a.m. ... presentation can be accessed by logging onto the web at ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...
... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...
... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...
Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3Scientists develop new technique that could improve heart attack prediction 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: